PRT-064040 nasal spray

Phase 2Small molecule

SSichuan Purity Pharmaceutical Technology Co., Ltd.

PRT-064040 nasal spray is one of 32 small molecule programs targeting Migraine. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

MigrainePhase 2

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Vyepti

Lundbeck

Preclinical

12 2

Savella

AbbVie

Preclinical

2 3

Botox

RRevance Therapeutics, Inc.

Preclinical

9 4

Cervidil

Pfizer

Preclinical

1 5

Adempas

Bayer

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

2 7

Nitrostat

VViatris Specialty LLC

Preclinical

2 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Pristiq

PPrism Pharmaceuticals

Preclinical

1 10

Botulinum Toxin a

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Migraine

NCT07304518

Clinical

Trials by Indication[1]

Migraine1 trial

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

Recruiting·SSichuan Purity Pharmaceutical Technology Co., Ltd.·Phase 2·NCT07304518·456 enrolled

Adult Subject1 trial

A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects

Completed·SSichuan Purity Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07016516·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PRT-064040 nasal spray. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRT-064040 nasal spray compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRT-064040 nasal spray. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Purity Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Purity Pharmaceutical Technology Co., Ltd.

PRT-064040 nasal spray

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Migraine1 trial

Adult Subject1 trial

References

Drug Info

Quick Facts

Related News